Johnson & Johnson

News

Johnson & Johnson's FcRn inhibitor nipocalimab has been awarded fast-track status by the FDA as a treatment for Sjogren's disease.

News

Genmab is facing increased pressure to deliver on its in-house pipeline after Johnson & Johnson exited a partnership on a Darzalex follow-up.

News

J&J wants to turn the screw in the psoriasis market with a new head-to-head trial pitting oral IL-23 drug icotrokinra against Stelara.

News

Johnson & Johnson has halted the development of aticaprant as a treatment for major depressive disorder, blowing a hole in its late-stage pipeline.

News

The FDA has approved the first generic versions of Johnson & Johnson's big-selling anticoagulant Xarelto.

News

Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by E coli looks all but defunct after they abandon a phase 3 trial.